no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
1 |
Antigenic Modulation and Rituximab Resistance
|
Taylor, Ronald P. |
|
2010 |
47 |
2 |
p. 124-132 9 p. |
article |
2 |
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
|
Beers, Stephen A. |
|
2010 |
47 |
2 |
p. 107-114 8 p. |
article |
3 |
CD20-Targeted Therapy: The Next Generation of Antibodies
|
van Meerten, Tom |
|
2010 |
47 |
2 |
p. 199-210 12 p. |
article |
4 |
Future Issues and Recent Issues
|
|
|
2010 |
47 |
2 |
p. A10- 1 p. |
article |
5 |
Rituximab-Associated Infections
|
Gea-Banacloche, Juan C. |
|
2010 |
47 |
2 |
p. 187-198 12 p. |
article |
6 |
Rituximab-Associated Neutropenia
|
Dunleavy, Kieron |
|
2010 |
47 |
2 |
p. 180-186 7 p. |
article |
7 |
Rituximab in Autoimmune Hematologic Diseases: Not Just a Matter of B Cells
|
Stasi, Roberto |
|
2010 |
47 |
2 |
p. 170-179 10 p. |
article |
8 |
Rituximab in Chronic Lymphocytic Leukemia
|
Jaglowski, Samantha M. |
|
2010 |
47 |
2 |
p. 156-169 14 p. |
article |
9 |
Rituximab in High-Grade Lymphoma
|
Zwick, Carsten |
|
2010 |
47 |
2 |
p. 148-155 8 p. |
article |
10 |
Rituximab in Indolent Lymphomas
|
Sousou, Tarek |
|
2010 |
47 |
2 |
p. 133-142 10 p. |
article |
11 |
Rituximab: Mechanism of Action
|
Weiner, George J. |
|
2010 |
47 |
2 |
p. 115-123 9 p. |
article |
12 |
Rituximab: Therapeutic Benefit! Vitamin R?
|
Mo, Clifton |
|
2010 |
47 |
2 |
p. 105-106 2 p. |
article |
13 |
Table of Contents
|
|
|
2010 |
47 |
2 |
p. A5-A6 nvt p. |
article |
14 |
Treatment of Splenic Marginal Zone Lymphoma: Splenectomy Versus Rituximab
|
Bennett, Michael |
|
2010 |
47 |
2 |
p. 143-147 5 p. |
article |